Subcutaneous Route Articles & Analysis
2 news found
” The Veloxis study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of VEL-101 or placebo when administered subcutaneously (SC) or intravenously (IV). Approximately 56 healthy participants will be enrolled and will undergo monitoring for 50 days. ...
Bexson believes the new utilities identified in this patent will allow safety, comfort and pharmacokinetics that greatly improve ketamine administration for multiple routes of administration, including subcutaneous. Formulated for subcutaneous delivery, Bexson's ketamine-based pain therapy aims to be an alternative to opioids. ...